Početna › Akutna bifentipska leukemija › Oregon
Kliničke studije za Akutna bifentipska leukemija u državi Oregon
6 studija za Akutna bifentipska leukemija traži sudionike na lokacijama u državi Oregon.
Gradovi u državi Oregon
Službeni tekst studije (engleski)
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 1/2
30 Days · Oba spola · Ažurirano 16. ruj 2026. · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
U tijeku regrutacijaFaza 3
365 Days – 25 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
U tijeku regrutacijaFaza 1/2
Do 22 godina · Oba spola · Ažurirano 25. kol 2026. · NCT04726241Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 7. srp 2026. · NCT07216443Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Oregon Health & Science University, Portland
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. pro 2024. · NCT05476770Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.